360 related articles for article (PubMed ID: 32464582)
1. Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Guevara C; Villa E; Rosas CS; Diaz V; Naves R
Mult Scler Relat Disord; 2020 Aug; 43():102224. PubMed ID: 32464582
[No Abstract] [Full Text] [Related]
2. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 will change MS care forever - No.
Preziosa P; Rocca MA; Filippi M
Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471
[No Abstract] [Full Text] [Related]
4. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Salama S; Ahmed SF; Ibrahim Ismail I; Alroughani R
Clin Neurol Neurosurg; 2020 Oct; 197():106203. PubMed ID: 32919242
[No Abstract] [Full Text] [Related]
5. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
6. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
7. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile.
Ciampi E; Uribe-San-Martin R; Cárcamo C
Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203
[No Abstract] [Full Text] [Related]
9. COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
[No Abstract] [Full Text] [Related]
10. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
12. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis, a treatable disease .
Doshi A; Chataway J
Clin Med (Lond); 2017 Dec; 17(6):530-536. PubMed ID: 29196354
[TBL] [Abstract][Full Text] [Related]
16. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
17. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
18. Update on disease-modifying treatments for multiple sclerosis.
Carrithers MD
Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
[TBL] [Abstract][Full Text] [Related]
19. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
20. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]